Chemists at C4X Discovery are using the virtual reality technology behind popular game Fortnite to visualize the structure of complex molecules. The tool, called 4Sight, has already been used to create a drug that is now in development to treat addiction.
25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms.
For U.K.-based C4X Discovery Holdings PLC, gaming engines are powering a more efficient drug-discovery process. The company uses the engines to discover molecules that help fight diseases like Alzheimer’s, Parkinson’s and ulcerative colitis, then licenses the resulting drugs to customers.
30 April 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces its interim results for the six months ended 31 January 2019.
17 December 2018 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that it has entered into an exclusive target discovery partnership with Horizon Discovery Group plc (“Horizon”, AIM: HZD), a global leader in the application of gene editing and gene modulation technologies. The partnership aims to validate novel synthetic lethal oncology targets that have been identified by Horizon’s cutting-edge CRISPR-Cas9 technology leading to the generation of potential new drugs for patients with limited effective treatments such as colorectal and lung cancer.
UK-based Pharmaceutical research firm C4X Discovery recently starting using Unreal Engine technology to visualize and manipulate 3-D molecules in virtual reality, with the potential to let scientists collaborate remotely in the virtual environment.
Early results point to novel approaches to drug discovery for this debilitating disease
Manchester and Oxford, UK, 6 December 2018: C4X Discovery Holdings plc (C4X.L) ("C4XD") and e-therapeutics plc (AIM: ETX, "e-therapeutics"), the network-driven drug discovery (NDD) company, are pleased to announce an update on their collaboration (announced 1st May 2018) to identify novel intervention strategies for the potential treatment of Parkinson’s Disease (PD).
...Take C4X, a drug discovery and development company that has a wholly-owned drug pipeline but is also developing molecules in partnership with pharma, biotech and academia.
Clive Dix, chief executive, says large pharmaceutical companies “are crying out for innovation and are struggling to get enough of it in their own organisation to have the best molecules coming through. They’re therefore going to . . . smaller, more innovative companies and licensing products from them”.
Its proprietary technologies include a tool that analyses genetic databases, and another that determines the 3D shape of drug molecules while they are still at the test-tube stage.